World ADC Event Series

🚨 Don’t Miss Out: Top Companies Revealed! 🚨 The 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit is returning to Boston - and it’s bringing together the key players shaping the future of ADC development. With the launch of the FDA’s Project Optimus and the evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. This highly focused summit unites 60+ experts in: • Clinical pharmacology • Pharmacokinetics & pharmacometrics • Bioanalysis & modelling 📅 Register by Friday, October 24 and save up to $500 Companies attending include: AbbVie | Amgen | Astellas Pharma | AstraZeneca | Bicycle Therapeutics Daiichi Sankyo US | Genentech | Gilead Sciences | GSK Explore the full agenda: https://ter.li/qvwa1x

𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐄𝐧𝐝𝐢𝐧𝐠 𝐒𝐨𝐨𝐧 – 𝐖𝐨𝐫𝐥𝐝 𝐀𝐃𝐂 𝐋𝐨𝐧𝐝𝐨𝐧 𝟐𝟎𝟐𝟔 The 16th World ADC London (23–26 February 2026) will once again bring together the European ADC community to drive next-generation bioconjugate innovation and advance ADCs toward becoming standard-of-care therapies. The full 4-day agenda is now available, featuring cutting-edge insights across ADC design, development, and manufacturing: https://ter.li/6c1uri With the largest registration discount expiring this 𝐅𝐫𝐢𝐝𝐚𝐲, 𝟐𝟒 𝐎𝐜𝐭𝐨𝐛𝐞𝐫, now is the final opportunity to secure the lowest-ever rate - saving up to £920 on your pass. Here are three key reasons to attend: 🟣Gain first-hand insights into novel ADC payload and design innovation and clinical progress 🟣Hear from leading experts and innovators shaping the field from Europe, North America, and Asia  🟣Network with 800+ leaders and decision makers at the largest gathering of the European ADC community 𝘋𝘰𝘯’𝘵 𝘮𝘪𝘴𝘴 𝘺𝘰𝘶𝘳 𝘤𝘩𝘢𝘯𝘤𝘦 𝘵𝘰 𝘣𝘦 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘵𝘩𝘦 𝘮𝘦𝘦𝘵𝘪𝘯𝘨 𝘥𝘦𝘧𝘪𝘯𝘪𝘯𝘨 𝘈𝘋𝘊 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘪𝘯 2026. #WorldADCLondon #ADC Recent sign-ups include Daiichi Sankyo, Affilogic, Debiopharm, and Boehringer Ingelheim!

𝐅𝐢𝐧𝐚𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐬 𝐄𝐱𝐩𝐢𝐫𝐢𝐧𝐠 𝐒𝐨𝐨𝐧! With less than three weeks to go, 𝘵𝘩𝘦 𝘣𝘶𝘻𝘻 𝘪𝘴 𝘳𝘦𝘢𝘭 and the global ADC community is gearing up to meet in California for the 16th World ADC San Diego. Join them here: https://ter.li/jzxty4 If you’re serious about staying ahead in the ADC space, this is the room to be in. Don’t miss your chance to join the world’s largest and longest-standing ADC meeting, bringing together the leaders shaping the future of ADCs. #WorldADC #ADC #AntibodyDrugConjugates

ADC innovation is accelerating - but are you tracking where it’s headed? Turn the surge of global filings into your competitive edge with Beacon Patents. Explore now: https://ter.li/6oikf1

I’m very excited to share the newly released programme for the 𝟭𝟲𝘁𝗵 𝗪𝗼𝗿𝗹𝗱 𝗔𝗗𝗖 𝗟𝗼𝗻𝗱𝗼𝗻 (23rd-26th February 2026), returning as the definitive forum for the European community to maximise the therapeutic index of ADCs. Looking to 2026, the community must prepare to tackle the consequences of ADC clinical crowding across Topo1 and MMAE payloads and established tumour targets. With anticipated ADC patient resistance, it is crucial to 𝗱𝗼𝘂𝗯𝗹𝗲 𝗱𝗼𝘄𝗻 𝗼𝗻 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁𝗶𝗮𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗲 𝗰𝗵𝗮𝗶𝗻 𝘁𝗼 𝘀𝗲𝗰𝘂𝗿𝗲 𝗮𝗻 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗔𝗗𝗖 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀. Check out the full 2026 programme here: https://ter.li/kybu3b Highlighting World ADC London’s commitment to stay at the forefront of ADC innovation, here’s a breakdown of what to take advantage of in 2026: 🌍 𝙂𝙡𝙤𝙗𝙖𝙡 𝘼𝘿𝘾 𝙎𝙥𝙚𝙖𝙠𝙚𝙧 𝙁𝙖𝙘𝙪𝙡𝙩𝙮: As the definitive forum for the European ADC community, the 2026 faculty features 110+ speakers from 𝗔𝘀𝗶𝗮, 𝗘𝘂𝗿𝗼𝗽𝗲 and 𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮 presenting a global perspective to forward-thinking ADC innovation 💡 𝗔𝗗𝗖 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁𝗶𝗮𝘁𝗶𝗼𝗻 𝗙𝗿𝗼𝗻𝘁 & 𝗖𝗲𝗻𝘁𝗿𝗲: Attend sessions on novel cytotoxic and non-cytotoxic payloads, dual payload conjugates, bispecific and biparatopic ADCs, and non-antibody conjugates to overcome patient resistance and advance ADCs to earlier-line patient therapies 🆕 𝗕𝗿𝗮𝗻𝗱-𝗡𝗲𝘄 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀: Committed to spotlighting refreshed perspectives on ADC development, don’t miss first-time presenters 𝗔𝗱𝗰𝗼𝗿𝗶𝘀 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮, ALX Oncology, Helix Biopharma Corp., 𝗥𝗮𝗱𝗶𝗮𝗻𝗰𝗲 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 and Salubris Biotherapeutics 🧑🔬 𝗔𝗗𝗖 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿, 𝗖𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻 & 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗥𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Expanding the speaker ecosystem, don’t miss sessions from the Paul-Ehrlich-Institut on ADC regulatory CMC, Paolo Tarantino on the power of ADC combinations, and diverse investor perspectives on the ADC Licensing, Investment & Partnering Panel Session Looking forward to reuniting the European ADC community in London! #WorldADC #WorldADCLondon #AntibodyDrugConjugates #Biopharma

Will you be attending the World ADC Event Series San Diego (Nov 3-6)? Don’t miss WuXi XDC CEO Jimmy L.'s talk on Nov 4—a must for anyone in bioconjugates. His session, “WuXi XDC: Technology Innovation and Global Expansion to Empower Bioconjugate Development from Concept to Commercialization,” dives into cutting-edge conjugation chemistry, payload-linker technologies, and how WuXi XDC’s global scale speeds bioconjugates from concept to commercialization. See you in San Diego! Let’s connect on booth 117! Click the link to schedule a chat with our team. https://lnkd.in/eCgHTVqf #conjugate #conjugates #bioconjugation #bioconjugate #bioconjugates #adc #adcs #antibodydrugconjugate #antibodydrugconjugates #cmc #cdmo #crdmo #biomanufacturing #bioprocessing

With just two months to go until the 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit, now is the time to find out more and explore the event guide. With the launch of the FDA’s Project Optimus and the ever-evolving clinical pharmacology guidelines for ADCs, the need to identify an optimal clinical dose that balances safety with efficacy has never been more evident. This summit offers a one-of-a-kind platform to connect with and learn from the leading minds shaping the future of ADC PK/PD. Get ready for insights from industry leaders such as: + Salaheldin Hamed, Astellas Pharma + Prabhas Jagdale, GSK + Werner Rubas, Sutro Biopharma, Inc. + Chris Beaver, Daiichi Sankyo US Explore the full event guide here: https://ter.li/qvwa1x

The Full 2026 Programme for the 16th World ADC London Is Live! Europe’s largest and pre-eminent ADC forum returns to secure the future of ADCs as standard-of-care therapies, featuring 110 global speakers from Europe, North America, and Asia across five end-to-end scientific streams. What’s New for 2026: ADC Differentiation Front & Centre: Explore innovation in cytotoxic & non-cytotoxic payloads, dual payload, bispecific & biparatopic designs, and non-antibody conjugates to combat payload resistance and drive next-gen ADC development Expanded Stakeholder Perspectives: For the first time hear from ADC clinicians, regulators & investors from institutions including Dana-Farber Cancer Institute, Paul Ehrlich Institute, Medicxi, and more. First-Time Presenting Companies: Discover fresh insights from Adcoris Biopharma, ALX Oncology, Helix Biopharma, Kivu Biosciences, Radiance Biopharma, and Salubris Bio, making their World ADC debut View the brand-new agenda now: https://ter.li/yucm5p #WorldADCLondon #ADC2026 #AntibodyDrugConjugates

In just 2 weeks’ time we will be opening the doors for the 3rd ADC Process Development Summit! This year’s event will bring together leading minds in ADC process development, from global pharma to pioneering biotechs and CDMOs, all focused on streamlining ADC manufacturing and accelerating regulatory success. With so many industry pioneers in one room – including, AbbVie, Pfizer, ADC Therapeutics, Bristol Myers Squibb, AstraZeneca – can you really afford to miss the opportunity to benchmark your processes, troubleshoot critical challenges, and advance ADC development with confidence? This is your chance to discuss, collaborate, and network directly with ADC experts driving process innovation across the field. Ready to join your peers? Secure your seat today: https://ter.li/6hzhq8 Explore the full event program: https://ter.li/6hzhq7